
Gasporox - Catching its breath after a strong H1 2023

Redeye provides an update on Gasporox after its Q3 2023 report. The report came in weaker-than-expected after H1 2023 results exceeding our expectations significantly. While we are pleased by AutoMap already receiving orders worth SEK3m, we have less optimistic Gasporox will manage to grow in H1 2024 due to the strong 2023 results. Thus, we reduce our fair value range while we remain optimistic about the long-term.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Gasporox - Catching its breath after a strong H1 2023](#)